Sun Pharma reports Q2FY20 results
Q2 gross sales at Rs 7,949 crores up 16 per cent YoY; Q2 net profit at Rs 1,064 crores up 12.6 per cent YoY
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sun Pharma
Sun Pharma Announces Licensing Agreement With CSIR-IICT
This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty…
Sun Pharma Shuts Two Clinical Pharmacology Units in Vadodara
To ensure optimal utilisation of clinical pharmacology units (CPUs) that conduct bio-equivalence studies, the company is…
Sun Pharma and CMS enter into a License Agreement for Cyclosporine A and Tildrakizumab in Greater…
Under the terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone…
Sun Pharma ties up with Samsung BioLogics
Samsung BioLogics will manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of…
Sun Pharma enters into derma segment
The company will co-promote Suncros brand across prescription and consumer channels to drive growth
Sun Pharma will focus on…
Sun Pharma announces divestment of US manufacturing units
Divests two units to Frontida BioPharm
Sun Pharma launches mobile app for asthma patients
RespiTrack seeks to enable doctors to track treatment progress of their patients and increase compliance to medication
ICGEB and Sun Pharma sign agreement to develop botanical drug to treat dengue
ICGEB will provide the technical know-how and pre-clinical expertise and Sun Pharma to develop this drug with appropriate…
Sun Pharma announces positive results of two phase-III CTs of Tildrakizumab
The IL-23p19 Therapeutic Antibody meets primary endpoints in both placebo-controlled studies and secondary endpoint in…